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Abstract. Sorafenib is currently used to treat advanced and/
or unresectable hepatocellular carcinoma (HCC), but the 
increase of the median survival was only 3 months. Moreover, 
sorafenib has severe side effects and patients develop resis-
tance quickly. Epigenetic alterations such as DNA methylation 
play a decisive role in the development and progression of 
HCC. To our knowledge, there are no studies that analysed the 
global DNA methylation changes in HCC cells treated with 
sorafenib. Using MeDip-chip technologies, we found 1230 
differentially methylated genes in HA22T/VGH cells treated 
with sorafenib compared to untreated cells. Gene ontology 
and pathway analysis allowed identifying several enriched 
signaling pathways involved in tumorigenesis and cancer 
progression. Among the genes differentially methylated we 
found genes related to apoptosis, angiogenesis and invasion, 
and genes belonging to pathways known to be deregulated 
in HCC such as RAF/MEK/ERK, JAK-STAT, PI3K/AKT/
mTOR and NF-κB. Generally, we found that oncogenes tended 
to be hypermethylated and the tumor suppressor genes tended 
to be hypomethylated after sorafenib treatment. Finally, we 
validated MeDip-chip results for several genes found differen-
tially methylated such as BIRC3, FOXO3, MAPK3, SMAD2 
and TSC2, using both COBRA assay and direct bisulfite 
sequencing and we evaluated their mRNA expression. Our 
findings suggest that sorafenib could affect the methylation 
level of genes associated to cancer-related processes and 
pathways in HCC cells, some of which have been previously 
described to be directly targeted by sorafenib.
Introduction
Hepatocellular carcinoma (HCC) is the most frequent 
primary malignancy of the liver. Globally, it is the fifth most 
common cancer in men and seventh among women. There 
are over half a million new HCC cases diagnosed annually 
worldwide, with Mediterranean countries such as Italy, 
Spain, and Greece that have intermediate incidence rates of 
10-20 per 100,000 individuals (1). The standard treatment for 
HCC patients with good prognosis is surgical resection, with 
the rate of five-year survival of 89-93% (2). However, for the 
majority of patients with an advanced and/or unresectable 
HCC the only therapeutic option is the oral multikinase 
inhibitor sorafenib (3). Sorafenib was developed in 1995. 
This molecule is a small drug developed by Bayer and Onyx 
that is able to inhibit strongly the activity of CRAF that was 
later named sorafenib. Besides affecting CRAF, sorafenib 
also inhibits BRAF, VEGFR-1, -2 and -3, PDGFR-β, FGFR1, 
c-Kit, Flt-3 and RET (4). Sorafenib reduces proliferation 
by inhibiting the activity of RAF in the MAPK pathway, 
induces apoptosis by blocking elF4E phosphorylation and 
the initiation of Mcl-1 translation, and reduces the tumor 
microvasculature targeting PDGFR-β and VEGFR-2/3 (5). 
In 2008, the SHARP clinical trial showed that the median 
overall survival increased from 7.9 months to 10.7 months 
in the group treated with sorafenib compared to placebo (6). 
Although HCC patients treated with sorafenib have an 
increase in survival time, sorafenib still presented very low 
rate of tumor response, suggesting the existence of some 
acquired mechanism of primary resistance. Some studies 
have suggested several mechanisms underlying the onset of 
sorafenib resistance in HCC such as the up regulation of Akt, 
the increased expression of EGFR and HER-3, the activation 
of epithelial-mesenchymal transition (EMT) process and cell 
autophagy (7).
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It is well known that hepatocarcinogenesis is a complex 
process, not only favoured by the accumulation of genetic 
alterations, but also by epigenetic alterations. In fact, there 
are many studies indicating the importance of epigenetic 
processes that have largely changed the view of HCC. These 
studies indicated that HCC presents many alterations of its 
epigenome such as global genomic DNA hypomethylation, 
gene-specific DNA hyper- or hypomethylation, abnormal 
expression of DNA methyltransferases and histone modifying 
enzymes, altered histone modification patterns, and aberrant 
expression of microRNAs and long non-coding RNA (8).
To our knowledge there are few studies in the literature 
regarding the epigenetic effects of sorafenib in cancer cells. 
In one study, A549 adenocarcinoma alveolar cancer epithelial 
cells were treated simultaneously with TGF-β1 and sorafenib 
and global changes to histone modification were determined. 
The authors demonstrated that sorafenib largely reversed the 
changes in histone modifications that occurred during EMT 
in A549 cells (9). In another study, it was demonstrated that 
the antiproliferative effect of sorafenib on HCC cells could 
be due to the degradation of the histone methyltransferase 
EZH2 promoted by sorafenib through the way of proteasome. 
Overexpression of EZH2 reduced the effects of sorafenib, while 
the siRNA against EZH2 increased the effect of the drug. It is 
assumed, therefore, that the epigenetic modifications mediated 
by EZH2 may be another molecular mechanism crucial for 
the acquisition of resistance to sorafenib (10). Furthermore, 
the interaction of sorafenib with microRNAs has been demon-
strated elsewhere (11). In our previous study, we found that the 
combined treatment of HA22T/VGH HCC cells with miR-193a 
and sorafenib led to further inhibition of proliferation compared 
to sorafenib treatment alone (11,12). However, DNA methylation 
has not been studied on global level in HCC cells treated with 
sorafenib. Herein, we evaluated the changes on DNA methyla-
tion profile in HCC cells treated with sorafenib. In particular, we 
used MeDip-chip technology to profile the DNA methylation 
variation in HA22T/VGH cells treated with sorafenib compared 
to untreated cells. The genes found differentially methylated 
by bioinformatics tools were then subjected to functional 
enrichment analysis and we found an enrichment of many 
gene ontology terms and molecular signalling pathways likely 
promoted by sorafenib treatment. Finally, we validated MeDip-
chip results for several genes using both COBRA assay and 
direct bisulfite sequencing and then we evaluated their mRNA 
expression (Fig. 1).
Materials and methods
Cell culture, sorafenib treatment and DNA and RNA extrac-
tion. HA22T⁄ VGH undifferentiated cells, kindly provided 
by N. D'Alessandro (University of Palermo, Palermo, Italy), 
were maintained in RPMI-1640 (Life Technologies) supple-
mented with 10% fetal bovine serum at 37˚C in a 5% CO2 
incubator. SKHep1Clone3 (SKHep1C3), selected from human 
HCC-derived cells (SKHep1: ATCC HTB-52), was main-
tained in Earle's MEM (Life Technologies) supplemented 
with 10% fetal bovine serum (Life Technologies) at 37˚C in 
a 5% CO2 incubator. Sorafenib (Nexavar®, BAY43-9006) was 
synthesized at Bayer Corporation and was dissolved in 100% 
DMSO (Sigma-Aldrich) and diluted in RPMI-1640 (Life 
Technologies) to the required concentration with a final DMSO 
concentration of 0.1%. Cells were cultured in 10 cm Ø plates up 
to almost confluence and were treated with sorafenib (5 µM) or 
solvent (0.1% DMSO) for 24 h. Genomic DNA and total RNA 
were extracted from treated and untreated cells using Wizard 
Genomic DNA purification kit (Promega) and TRIzol reagent 
(Life Technologies), respectively, according to the manu-
facturer's instructions, and the nucleic acid quantifications were 
performed using NanoDrop (Thermo Fisher Scientific).
MeDip-chip. The global DNA methylation profiles of 
cells treated with sorafenib or left untreated were obtained 
by methylated DNA immunoprecipitation coupled with 
Affymetrix Human Promoter 1.0R Tiling Arrays (MeDip-
chip) using a modification of the Affymetrix chromatin 
immunoprecipitation assay protocol. Genomic DNA from 
sorafenib treated and untreated cells was fragmented using 
micrococcal nuclease (New England Biolabs) to obtain DNA 
fragments ranging from 200 to 500 nucleotides and used 
them as input (IN) DNA. Agilent Bioanalyzer with the RNA 
Figure 1. Schematic flow chart of the experimental design followed.
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6000 Nano LabChip kit was used to check the size of frag-
mented DNA. Part of IN DNA (4 µg) was immunoprecipitated 
(IP) with 10 µl of anti-5-methylcytosine Antibody (Eurogentec, 
BI-MECY-0100) using the MeDip protocol (13), with minor 
modifications. The antibody-DNA complexes were immuno-
precipitated using Dynabeads® Protein G immunoprecipitation 
kit (Life Technologies) and the methylated enriched DNA was 
purified by standard phenol/chloroform procedure and precipi-
tated with isopropanol. The MeDip was performed in duplicate 
for each DNA sample starting with initial fragmentation step. 
A total of 200 ng of IN and IP DNA was amplified with the 
Affymetrix Chromatin Immunoprecipitation Assay Protocol. 
Hybridization on Human Promoter 1.0R array was performed 
using the reagents contained in GeneChip® Hybridization, 
Wash, and Stain kit (Affymetrix) using GeneChip hybridiza-
tion oven 640 (Affymetrix). Array washing and staining was 
performed with the use of the Fluidics Station 450 (Affymetrix). 
Arrays were scanned with the GeneChip Scanner 3000 7G 
(Affymetrix) and raw data were extracted with GeneChip 
Operating System (GCOS) software from Affymetrix. In total 
3 arrays per each cellular condition (2 IP DNA and 1 IN DNA) 
were performed. IP and IN DNA data have been deposited in 
the National Center for Biotechnology Information (NCBI) 
Gene 97 Expression Omnibus (GEO) data repository, and are 
accessible (GSE72257).
Data analysis. The raw data were imported into Partek 
Genomics Suite (PGS) software version 6.6, normalized with 
the RMA algorithm and converted to log2 values. Hierarchical 
clustering and principal component analysis were performed 
on the raw data to assess the quality and reproducibility of 
the sample. For each cellular condition, the two IP CEL files 
were normalized through subtraction of log2 IN signal inten-
sity of each of 4.6 million array probes to log2 IP signal. The 
differences between sorafenib-treated and untreated cells were 
analyzed using ANOVA. Significant differentially methylated 
regions (DMR) were obtained using the MAT algorithm 
(model-based analysis of tiling arrays algorithm) (14) with 
the following parameters: P-value threshold <0.001, sliding 
window = 2,000 bp, minimum number of probes in a 
region = 10. DMR with a positive or negative MAT score were 
considered hypermethylated or hypomethylated, respectively, 
in sorafenib-treated cells compared to untreated cells. Using 
PGS function, each DMR was associated to its nearest gene 
of the human genome. The genomic coordinates of each DMR 
were calculated based on UCSC human genomic assembly 
version 18. The ratio between CpG observed and CpG 
expected for each DMR was calculated using the following 
formula: Observed/expected CpG = number of CpG x (DMR 
length) / (number of C x number of G). In order to study the 
effect of DNA methylation changes on promoters and gene 
bodies only DMR between -5,000 bp from TSS and +5,000 bp 
from the end of the annotated gene were included for the next 
analyses. For functional enrichment analysis of gene ontology 
terms and molecular signaling pathway the following tools 
were used: DAVID (https://david.ncifcrf.gov/), WebGestalt 
(http://bioinfo.vanderbilt.edu/webgestalt/), Enrichr (http://
amp.pharm.mssm.edu/Enrichr/) and oPOSSUM 3.0 (http://
opossum.cisreg.ca/oPOSSUM3/). A more stringent cut-off 
(P-value <0.0008) associated to DMR was applied to remove 
non-relevant genes and reduced the list of DMR and corre-
sponding genes used for performing the following functional 
enrichment analyses.
COBRA and direct bisulfite sequencing quantification of CpG 
methylation. In order to validate the DNA methylation status in 
a set of genomic regions detected as hypermethylated (positive 
MAT score) or hypomethylated (negative MAT score) by the 
MeDip-chip profiling we performed combined bisulfite restric-
tion analysis (COBRA) and direct bisulfite sequencing for 
quantitative DNA methylation analysis, and using the original 
DNA samples for sorafenib treated and untreated cells that were 
Table I. Distribution of the 1,280 DMR based on CpG density.
 Observed to expected CpG  No. of Hypermethylated  Hypomethylated
DMR ratio (Obs/Exp CpG)a DMR DMR (%) DMR (%)
Total DMR Obs/Exp CpG ≥60% 292 2.7 97.3
 60% < Obs/Exp CpG <30% 364 55.5 44.5
 Obs/Exp CpG ≤30% 624 76.3 23.7
DMR in promoter region Obs/Exp CpG ≥60% 215 1.9 98.1
 60% < Obs/Exp CpG <30% 114 50.9 49.1
 Obs/Exp CpG ≤30% 194 77.8 22.2
DMR in gene body Obs/Exp CpG ≥60%   60 6.7 93.3
 60% < Obs/Exp CpG <30% 223 58.7 41.3
 Obs/Exp CpG ≤30% 377 75.3 24.7
DMR in CDS end of the gene Obs/Exp CpG ≥60%   17 0 100
 60% < Obs/Exp CpG <30%   27 48.1 51.9
 Obs/Exp CpG ≤30%   53 77.4 22.6
aObserved to expected CpG ratio = number of CpG x (DMR length) / (number of C x number of G).
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used in the MeDip-chip experiment. The gene specific bisulfite 
primers were designed to overlap five MAT detected DMR 
using the MethPrimer Software (BIRC3: forward, 5'-TTA 
GTTTGTTTGGTTGTGAAGAGAA-3', reverse, 5'-ACTCC 
CTAACCCATACCCTATACAC-3'; FOXO3 forward, 5'-GGG 
TTGTTTTTTGAGGATT-3', reverse, 5'-ACCAACCCCT 
TACCCTAAA-3'; MAPK3 forward, 5'-TTAGTTTTTTAG 
GAGGTTAAGGTGG-3', reverse, 5'-CCACAAACTATAAA 
CAAAAAATCTCC-3'; SMAD2 forward, 5'-GGGGTTT 
GTAGGGGTTTGT-3', reverse, 5'-TCCCAACCATTAAA 
AAACATC-3'; TSC2 forward, 5'-GTTTTTGTGTTATGATT 
TTGGGAA-3', reverse, 5'-ACATCCATCCACTACAAAA 
CAAAAT-3'). Bisulfite treatment of genomic DNA was 
performed using EZ DNA Methylation kit (Zymo Research). 
For COBRA analysis the restriction enzymes TaqI and 
HpyCH4IV (New England Biolabs) were used to examine the 
methylation status of the amplified regions. In brief, 100-150 ng 
of the amplified products were digested with the restriction 
enzymes, which digest methylated DNA but not unmethylated 
DNA. The digested DNA was electrophoresed on 3% agarose 
gels in 1X TBE, and visualized by ethidium bromide staining. 
We used a UV image analyzer to quantify the integrated 
optical density (IOD) of the bands. Methylation level (%) for a 
specific cytosine was defined as the sum of the IOD of the 
shifted bands divided by the IOD of all bands in each lane. 
All experiments were repeated twice to assess the reproduc-
ibility of results.
For direct bisulfite sequencing analysis the amplified prod-
ucts obtained previously were purified and sequenced on an 
Applied Biosystems 3130xl Genetic Analyzer. The sequencing 
reactions were performed using Bigdye Terminator v1.1 Cycle 
Sequencing kit (Life Technologies) and purified with Performa 
Ultra 96-Well Plate (EdgeBio, Gaithersburg, MD, USA). The 
abi files were analyzed with Accelrys DS Gene 1.5 (Accelrys). 
Since bisulfite treatment does not convert methylated cytosine 
to uracil, the cytosine chromatogram peaks at each CpG 
location will correspond to the degree of methylation at that 
site within a given sample. Likewise, the thymine chromato-
gram peaks will correspond to the degree of cytosines that 
were not methylated. Furthermore, the relative size of these 
peaks will be proportionally related to the total percentage of 
cytosine bases that were methylated. Therefore, according to 
Parrish et al (15), methylation levels for each CpG site within 
the DNA amplicon can be quantified by measuring the ratio 
between peak height values of cytosine (C) and thymine (T), 
yielding the basic equation for the methylation percentage to 
be [C/(C+T) x100]. If the reverse primer was used, the guanine 
(G) and adenine (A) peak heights should be used instead, 
yielding the equation [G/(G+A) x100]. Each amplicon was 
sequenced in triplicate to assess the reproducibility of results.
RT-qPCR expression analysis. In order to investigate 
the relationship between DNA methylation changes and 
gene expression in sorafenib-treated and untreated cells 
Figure 2. Differentially methylated regions (DMR) and associated genes in HA22T/VGH cells treated with sorafenib. Distribution of the 1,280 DMR based 
on the position respect the TSS of the gene (A) and chromosomes (B). (C) The graph shows the class of the genes catalogued with online repository of HGNC 
(HUGO gene nomenclature committee) and the corresponding percentage.
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(HA22T/VGH and SKHep1C3), RT-qPCR was performed to 
determine the gene expression of several genes whose DNA 
methylation status was validated previously with COBRA 
and direct bisulfite sequencing. An amount of 1 µg of total 
RNA was retrotranscribed using M-MLV-RT enzyme (Life 
Technologies) and pre-designed primers used for qPCR vali-
dation were purchased from Bio-Rad (Hercules, CA, USA). 
GoTaq qPCR Master Mix was supplied by Promega.
The mRNA expression of BIRC3, FOXO3, MAPK3, 
SMAD2 and TSC2 genes was evaluated by qPCR using 
PrimePCR™ SYBR® Green Assay (Bio-Rad, BIRC3: 
qHsaCID0013381; FOXO3: qHsaCID0023235; MAPK3: 
qHsaCID0010939; SMAD2: qHsaCID0022031; TSC2: 
qHsaCID0018594; YWHAZ: qHsaCID0013897). The rela-
tive quantification of the expression in sorafenib-treated HCC 
cells compared to untreated cells was based on ∆∆Ct method. 
YWHAZ was used as housekeeping gene and untreated cells 
were used as a reference sample. We chose YWHAZ because 
it has been shown to have a constant expression during the 
process of apoptosis in tumor cell lines (16). qPCR experiment 
was performed twice. For each qPCR reaction, we used 20 ng 
of cDNA. Each gene in the two cellular conditions was assayed 
in triplicate. After qPCR reaction, denaturation curve was 
performed to ensure the specificity of the primers.
Results
Detection of global DNA methylation changes in HCC 
sorafenib-treated cells by using Human Promoter array tech-
nology. We previously demonstrated that HA22T/VGH cells 
were sensitive to sorafenib (11). To assess whether these undif-
ferentiated HCC cells treated with sorafenib displayed genome 
wide changes in DNA methylation, we performed methylated 
DNA immunoprecipitation (MeDip) followed by hybridization 
on tiling array. We used MeDip in combination with Human 
Promoter 1.0 Tiling array platform to identify changes of hypo- 
and hypermethylation with greater sensitivity in HA22T/VGH 
cells treated with sorafenib in comparison to cells treated with 
vehicle (DMSO) only.
We detected the differentially methylated regions (DMR) 
in HA22T/VGH treated with sorafenib using untreated cells as 
baseline. Significant DMR were obtained by PGS using ANOVA 
and MAT algorithm with specific parameters (see Materials 
and methods). We considered only DMR between -5,000 bp 
from the TSS and +5,000 bp from the end of the coding 
DNA sequence (CDS) of the genes. From the comparison, we 
obtained 1,280 DMR corresponding to 1,230 distinct anno-
tated genes, with 46.4% of hypomethylated DMR and 53.6% 
Table II. Molecular signaling pathways found enriched by DAVID.
    Adjusted
    P-value
Category Term Count P-value Benjamini Genes
BIOCARTA EGF signaling pathway 10 1.02E-05 2.06E-03 CSNK2A3, FOS, HRAS, JAK1, 
     MAPK3, MAPK8, PIK3CA, 
     SHC1, STAT3, STAT5A
BIOCARTA PDGF signaling pathway   9 4.57E-05 4.58E-03 CSNK2A3, FOS, HRAS,
     JAK1, MAPK3, MAPK8, 
     SHC1, STAT3, STAT5A
BIOCARTA IL 2 signaling pathway   8 1.42E-04 9.49E-03 CSNK2A3, FOS, HRAS, JAK1, 
     MAPK3, MAPK8, SHC1, STAT5A
BIOCARTA EPO signaling pathway   7 4.44E-04 2.21E-02 CSNK2A3, FOS, HRAS, MAPK3, 
     MAPK8, SHC1, STAT5A
BIOCARTA TPO signaling pathway   7 8.39E-04 3.32E-02 CSNK2A3, FOS, HRAS, MAPK3, 
     MAPK8, SHC1, STAT5A
The hypomethylated genes (negative MAT-score) are in bold.
Table III. Genes of EGF signaling pathway found differently 
methylated.
Gene MAT score  OG/TSG
HRAS  -9.91 OG
MAPK8 (JNK1) -9.62 TSG
SHC1  -9.34 TSG/OG
STAT3  9.84 OG
STAT5A  9.94 OG
FOS  10.04 OG
JAK1  10.18 OG
PIK3CA  10.32 OG
CSNK2A3  11.02 -
MAPK3 (ERK) 12.42 OG
OG/TSG = evidence that a given gene acts as oncogene (OG), tumor 
suppressor gene (TSG) or neither (-) according with literature data.
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of hypermethylated DMR (Fig. 2A). To have a general view 
of the post-sorafenib genomic landscape we considered the 
distribution of DMR respect to TSS and CpG density, and the 
frequency of DMR in the different chromosomes.
Considering the position of DMR regarding TSS we found 
40.9% of DMR localized in promoter region, 51.6% in gene 
body and 7.6% in CDS end of the gene. In particular, DMR 
in promoter regions presented more hypomethylated DMR, 
whereas DMR in gene bodies presented the opposite trend 
with more hypermethylated DMR (Fig. 2A). Calculating the 
CpG density for each DMR with the observed to expected 
CpG ratio (obs/exp CpG) formula we found that 22.8% of 
DMR have an obs/exp CpG >60%, 28.4% of DMR an obs/exp 
CpG between 60-30%, and 48.8% of DMR with an obs/exp 
CpG <30% (Table I). In particular, we found that the DMR 
with an obs/exp CpG >60% were almost exclusively subjected 
to a hypomethylation phenomenon, whereas the DMR with an 
obs/exp CpG <30% were preferentially subjected to a hyper-
methylation phenomenon. This trend was repeated regardless 
whether the DMR was in the promoter region, in the gene 
body or in the CDS end of the gene (Table I). Then, observing 
the frequency of distribution in the different chromosomes, we 
found that the 1,280 DMR were distributed quite uniformly 
along the 24 chromosomes according with their gene density 
(Fig. 2B). However, some chromosomes showed more hyper-
methylated DMR (chr 1, chr 12, chr 17 and chr 22) whereas 
others showed more hypomethylated DMR (chr 4 and chr Y). 
Finally, to have a general view of the gene classes involved we 
catalogued the 1,230 differentially methylated genes by using 
the online repository of HGNC (HUGO gene nomenclature 
committee), and we found that the majority of DMR were 
close to a protein coding gene (Fig. 2C).
Functional enrichment analysis of the 1,230 genes found 
differentially methylated in the sorafenib-treated cells. In 
order to assign a biological meaning to the 1,230 genes found 
differentially methylated in sorafenib-treated cells compared 
to untreated cells in MeDip-chip analysis, we conducted a 
functional enrichment analysis using different online tools.
DAVID identified 18 enriched annotation terms associ-
ated to our gene list. In particular, five BIOCARTA signaling 
pathways were related to receptor tyrosine kinase (RTK) 
signal transduction (Table II). Of note were the changes in 
DNA methylation in the genes of these pathways. For example, 
among the 10 genes found differentially methylated in the EGF 
pathway, 7 oncogenes (OG) were hypermethylated and 2 tumor 
suppressor genes (TSG) were hypomethylated (Table III). This 
occurred in a similar way also in the other 4 pathways. The 
results of this analysis may indicate that sorafenib modi-
fied the level of DNA methylation of HA22T/VGH cells in 
Figure 3. Examples of molecular signaling pathways found enriched by WebGestalt. (A) MAPK signaling pathway. (B) IL-3 signaling pathway. The tables report 
the genes whose level of methylation was changed after the treatment of HA22T/VGH with sorafenib. Negative and positive MAT-scores indicate a given gene 
hypomethylated or hypermethylated, respectively. The column ‘OG/TSG’ indicates the presence of evidence in published reports that a given gene acts as onco-
gene (OG), tumor suppressor gene (TSG) or neither (-). Histograms indicate the number of OG or TSG that were hypomethylated or hypermethylated in our study.
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key genes of RTK signal transduction pathways on which 
sorafenib acts directly.
Gene ontology analysis performed by WebGestalt 
found 16 terms significantly enriched. In particular, the 
following 3 terms had a lower level of abstraction and were 
more specific: ‘Sequence-specific DNA binding RNA poly-
merase II transcription factor activity’, ‘Structure-specific 
DNA binding’ and ‘Double-stranded DNA binding’. The first 
term was related to transcription factors that bind the RNA 
polymerase II (29 genes). The second and third term (son of 
the second term) are related to transcription factors that bind 
directly to DNA (24 and 20 genes, respectively). Among 
these genes, we found several transcription factors relevant 
in tumorigenesis and/or cancer progression such as FOXO3, 
STAT3 and STAT5A that displayed a change in DNA meth-
ylation level following sorafenib treatment. Pathway analysis 
performed by WebGestalt found 10 Wikipathways in our 
list of genes (Table IV). The genes that occur most often in 
these pathways were ATF2, CDKN1A, FOS, FOXO3, HRAS, 
IKBKG, JAK1, MAP2K2, MAP2K7, MAP3K14, MAP3K8, 
MAPK3, MAPK8, PIK3CA, PRKCZ, RAC1, SHC1, SHC2, 
STAT3, STAT5A, and STAT5B. In the literature, there is 
evidence that these genes have a role in tumorigenesis and/or 
cancer progression. We found a strong tendency of OG to 
be hypermethylated and TSG to be hypomethylated after 
sorafenib treatment (Fig. 3). This may indicate that sorafenib 
Table IV. Molecular signaling pathways found enriched by WebGestalt tool.
 Molecular
 signaling Genes Raw Adjusted
Category pathway count P-value P-value Genes
Wikipathway Insulin 20 4.65E-08 6.88E-06 FOS, FOXO3, GRB10, HRAS, MAP2K2, 
 signaling    MAP2K7, MAP3K14, MAP3K8, 
 pathway    MAPK3, MAPK8, MINK1, PIK3CA, 
     PRKAA2, PRKCZ, RAC1, RPS6KA4, 
     SHC1, SHC2, TRIB3, TSC2
Wikipathway Kit receptor  12 3.16E-07 1.65E-05 FOS, FOXO3, GRB10, HRAS, MAP2K2, 
 signaling    MAPK3, MAPK8, SHC1, STAT3, 
 pathway    STAT5A, STAT5B
Wikipathway Prolactin 14 3.35E-07 1.65E-05 FOS, HRAS, JAK1, MAP2K2, MAPK3, 
 signaling    MAPK8, PIK3CA, RAC1, SHC1, STAT3, 
 pathway    STAT5A, STAT5B, TEC, ZAP70
Wikipathway AGE-RAGE 12 1.53E-06 5.66E-05 ATF2, LGALS3, MAPK3, MAPK8, 
 pathway    MMP7, PRKCZ, RAC1, SHC1, 
     SMAD2, STAT3, STAT5A, STAT5B
Wikipathway IL-2 signaling  10 2.13E-06 6.29E-05 FOS, FOXO3, HRAS, JAK1, MAP2K2,
 pathway    MAPK3, SHC1, STAT3, STAT5A, 
     STAT5B
Wikipathway IL-3 signaling 10 2.55E-06 6.29E-05 FOS, HRAS, JAK1, MAPK3, MAPK8,
 pathway    PRKACA, SHC1, STAT3, STAT5A, 
     STAT5B
Wikipathway MAPK  17 5.33E-06 0.0001 ATF2, DAXX, FOS, HSPA1B, IKBKG, 
 signaling    IL1R1, MAP2K2, MAP2K7, MAP3K14, 
 pathway    MAP3K8, MAPK3, MAPK8, MINK1,
     PRKACA, PRKCZ, RAC1, STK3
Wikipathway IL-5 signaling   9 6.07E-06 0.0001 FOXO3, FOS, JAK1, MAP2K2, MAPK3, 
 pathway    SHC1, STAT3, STAT5A, STAT5B
Wikipathway AMPK 10 1.65E-05 0.0002 TSC2, CAB39, CDKN1A, CPT1A, FASN, 
 signaling    PFKFB3, PIK3CA, PLCB1, PRKAA2,
 pathway    PRKACG
Wikipathway TCR signaling  13 1.03E-05 0.0002 ATF2, FOS, HRAS, IKBKG, IRF4, 
 pathway    MALT1, MAP2K2, MAP3K14, MAP3K8, 
     MAPK3, MAPK8, SHC1, ZAP70
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Table V. Non-coding genes found differently methylated and associated with the tumorigenesis and/or cancer progression.
   CpG 
   observed/
 DMR Num. CpG  MAT DMR
Gene length CpG expected P-value score position Note
ATXN8OS  2110   11 0.18 3.69E-04 -10.15 Gene body Antisense RNA. 
       Implicated in localization
       and activity of splicing factors
C1RL-AS1  3076   34 0.16 5.16E-04 10.24 Gene body Antisense RNA
CACNA1C-AS1  2453 117 0.58 1.66E-04 -11.01 Promoter region Antisense RNA
CECR5-AS1  2036   26 0.24 3.87E-04 10.50 Gene body Antisense RNA
EPHA1-AS1  985     9 0.25 5.16E-04 10.21 Gene body Antisense RNA. Diseases
       associated with EPHA1-AS1
       include Alzheimer's disease
FAM41C  2699   53 0.36 1.47E-04 -11.08 Gene body lncRNA class
FAM66D  2279   42 0.41 2.58E-04 11.10 Gene body Antisense RNA
GATA6-AS1  2895 188 0.88 4.06E-04 -10.07 Promoter region Antisense RNA
HOTTIP  1434   20 0.39 2.21E-04 -10.65 Promoter region Antisense RNA. Role in cancer (48)
HOXB-AS3  4175 222 0.61 1.66E-04 -10.87 Gene body Antisense RNA. 
       Diseases associated with
       HOXB-AS3 include obesity
LINC00029  2382 105 0.47 7.01E-04 -9.49 Gene body Long intergenic non-protein coding
LINC00174  1674   34 0.42 4.24E-04 -10.00 Gene body Long intergenic non-protein coding
LINC00261  1054     9 0.19 3.69E-05 -13.06 Gene body Long intergenic non-protein coding
LINC00261  2135 104 0.66 7.01E-04 -9.41 Gene body Long intergenic non-protein coding
LINC00277  3609   52 0.28 2.58E-04 11.03 Promoter region Long intergenic non-protein coding
LINC00319  3036 124 0.42 9.22E-05 -12.22 Promoter region Long intergenic non-protein coding
LINC00539  2157   77 0.59 3.32E-04 -10.20 Gene body Long intergenic non-protein coding
LINC00539  964   14 0.22 3.87E-04 10.53 Gene body Long intergenic non-protein coding
LINC00628  2253   33 0.24 5.53E-05 13.09 CDS end of the gene Long intergenic non-protein coding
LINC00637  2399 213 0.94 7.56E-04 -9.35 Gene body Long intergenic non-protein coding
LINC00643  679     5 0.24 5.53E-05 13.24 Gene body Long intergenic non-protein coding
LINC00663  379     7 0.45 1.84E-05 -13.75 CDS end of the gene Long intergenic non-protein coding
LINC00857  3166 179 0.67 7.01E-04 -9.42 Gene body Long intergenic non-protein coding
LINC00957  2385 142 0.55 1.47E-04 -11.09 Gene body Long intergenic non-protein coding
LINC00999  2549 109 0.41 1.84E-05 -14.02 Gene body Long intergenic non-protein coding
LINC01002  2343 114 0.46 9.22E-05 -12.24 Gene body Long intergenic non-protein coding
LINC01056  663   45 0.68 4.06E-04 -10.10 Gene body Long intergenic non-protein coding
MALAT1  2205   73 0.51 1.84E-05 16.14 CDS end of the gene IncRNA. Role in cancer (47)
MIR149  3820 308 0.64 1.29E-04 -11.22 Gene body miRNA. Role in cancer (49)
MIR3939  1740   10 0.15 4.98E-04 10.26 CDS end of the gene  miRNA
MIR4635  2310 128 0.55 1.29E-04 -11.27 Gene body miRNA
MIR4683  2321 281 0.96 4.06E-04 -10.05 Promoter region miRNA
MIR5091  1362 106 0.86 1.11E-04 -11.65 Gene body miRNA
MIR5187  2601   31 0.17 4.42E-04 10.39 Gene body miRNA
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could trigger the hypermethylation of several OG and the 
hypomethylation of other TSG as downstream effect. In addi-
tion, the pathway analysis revealed that many genes belonging 
to MAPK cascade and JAK-STAT signaling pathway (IL-2/3/5 
signaling pathways), known to be involved in sorafenib mecha-
nism of action, had a change in the level of methylation after 
sorafenib treatment (Fig. 3). The MAPK signaling pathway 
showed a MEK gene (MAP2K2) and an ERK gene (MAPK3) 
hypermethylated after sorafenib treatment. In contrast, genes 
belonging to the JNK signaling pathway (MAP2K7, MAPK8) 
were hypomethylated indicating a possible activation of this 
pathway (Fig. 3A). Regarding the JAK-STAT pathway, the 
genes JAK1, STAT3, STAT5A and STAT5B were hypermeth-
ylated with probable inhibition of this pathway (Fig. 3B).
In summary, among the 1,230 differentially methylated 
genes identified by functional enrichment analysis, several 
genes had a role in tumorigenesis and/or cancer progres-
sion described in literature. Some of these genes were 
associated with functions linked to apoptosis, invasion and 
angiogenesis. Moreover, we found that sorafenib affected the 
methylation level of genes belonging to important signaling 
pathways such as RAF/MEK/ERK, JNK, JAK-STAT, PI3K/
AKT/mTOR and NF-κB.
Non-coding genes found differentially methylated in sorafenib-
treated cells. Among the 1,230 differentially methylated genes, 
47 were non-coding genes (Table V) with 16 antisense RNAs, 
20 lncRNAs including 15 lincRNAs, 7 microRNAs, three small 
nucleolar RNAs, and one small nucleolar RNA. In particular, 
MALAT1, HOTTIP, miR-149 and miR-675 are known to be 
associated with the tumorigenesis and/or cancer progression.
Validation of MeDip-chip results by COBRA assay and direct 
bisulfite sequencing of the genes BIRC3, FOXO3, MAPK3, 
SMAD2 and TSC2. In order to validate the methylation status 
of the genes found hypomethylated or hypermethylated in 
MeDip-chip experiment, we performed quantitative analysis 
of CpGs by COBRA assay and direct bisulfite sequencing. 
Among the OGs and TSGs found differentially methylated, 
we chose to validate the following genes: BIRC3, FOXO3, 
MAPK3, SMAD2 and TSC2 (Table VI). These 5 genes were 
chosen for their biological significance, for the location of 
the DMR in the associated gene and for the number of CpGs 
contained in the DMR. Our aim was to better understand the 
relationship between DNA methylation in regions with high or 
low density of CpGs located in different portions of the gene 
(promoter or intragenic) and gene expression. In HA22T/VGH 
cells the DMR relative to BIRC3 and MAPK3 were found 
hypermethylated in sorafenib-treated cells by MeDip-chip 
experiment. COBRA assay results are in line with these find-
ings and confirmed that the level of DNA methylation in this 
DMR was higher in sorafenib treated cells compared to the 
untreated cells (Fig. 4A and B). 
Direct bisulfite sequencing on BIRC3 DMR found that 
57.14% of CpGs analysed showed a hypermethylation trend 
in sorafenib-treated compared to -untreated cells and 14.29% 
Table V. Continued.
   CpG 
   observed/
 DMR Num. CpG  MAT DMR
Gene length CpG expected P-value score position Note
MIR675  3245 150 0.51 7.37E-05 -12.38 Promoter region miRNA. Role in cancer (50)
MRPL23-AS1  2003   85 0.42 7.74E-04 -9.28 Promoter region Antisense RNA
MYLK-AS1  2516 138 0.70 1.84E-05 -14.32 Gene body Antisense RNA
RNF219-AS1  2572 108 0.64 3.69E-04 -10.14 Gene body Antisense RNA. SNP associated
       with the regulation of blood
       pressure and alcohol consuming
SNHG18  2171 182 0.75 7.74E-04 -9.26 Gene body Small nucleolar RNA
SNORA51  2385   52 0.33 6.82E-04 9.97 Gene body Small nucleolar RNA
SNORD52  2303   69 0.50 2.77E-04 -10.33 Gene body Small nucleolar RNA
SPANXA2-OT1  2060   15 0.20 5.16E-04 10.21 Gene body Antisense RNA
SPATA41  2102   13 0.19 1.66E-04 -11.01 Promoter region lncRNA class
TOB1-AS1  2251 209 0.83 7.74E-04 -9.31 Gene body Antisense RNA
TTC28-AS1  2534   47 0.45 2.40E-04 11.15 Gene body Antisense RNA. Associated
       with obesity
ZNRD1-AS1  1415     8 0.11 7.74E-04 9.83 Gene body Antisense RNA. Associated 
       with Graves' disease
       and systemic lupus erythematosus
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of CpGs showed a hypomethylation trend (Fig. 5A). Direct 
bisulfite sequencing of MAPK3 DMR displayed that 90.91% of 
CpGs analysed showed a hypermethylation trend in sorafenib-
treated compared to untreated cells, and 0% of CpGs showed a 
hypomethylation trend (Fig. 5B). The DMR relative to TSC2, 
FOXO3 and SMAD2 were found hypomethylated in MeDip-
chip experiment. COBRA assay carried out on TSC2 DMR 
confirmed that the level of DNA methylation in this DMR was 
lower in sorafenib-treated cells than -untreated cells (Fig. 4C). 
Moreover, direct bisulfite sequencing found that 84% of CpGs 
analysed showed a hypomethylation trend in sorafenib-treated 
cells, and 8% of CpGs analysed showed a hypermethylation 
trend (Fig. 5C and F) confirming the hypomethylation trend 
of TSC2 gene found by MeDip-chip experiment. For DMR 
relative to FOXO3 and SMAD2, direct bisulfite sequencing 
displayed 65.12% of CpGs analysed with a hypomethyl-
ation trend in sorafenib-treated cells and 25.58% of CpGs 
analysed with a hypermethylation trend for FOXO3 DMR 
Figure 4. Validation of MeDip-chip results by COBRA assay in sorafenib treated and untreated HCC cells. (A) The DMR associated to BIRC3 gene was 
1,944 bp long and the primers were designed to amplify a 758 bp fragment from nucleotides 1,032 to 1,790 relative to the DMR start. The digested bands 
(610 and 148 bp) indicate the presence of methylation (red arrows). The band at the top (758 bp) corresponds to undigested DNA (black arrow). The histograms 
indicate the level of methylation in cytosine 611 in sorafenib treated cells and untreated cells by COBRA analysis. The results indicated a hypermethylation 
of cytosine 611 in sorafenib treated cells. (B) The DMR associated to MAPK3 gene was 2,255 bp long and the primers were designed to amplify a 430 bp 
fragment from nucleotides 1,660 to 2,090 relative to the DMR start. The digested bands (378 and 307 bp) indicate the presence of methylation (red arrows). The 
band at the top (430 bp) corresponds to undigested DNA (black arrow). The bands of 52 and 71 bp were not visible on the gel. The histograms indicate the level 
of methylation in cytosine 53 and cytosine 360 in sorafenib treated cells and untreated cells by COBRA analysis. The results indicated a hypermethylation of 
cytosine 53 and cytosine 360 in sorafenib treated cells. All the assays were performed using 3.0% gel in 1X TBE. Error bars of the histograms are referred to 
standard deviation of the means of two experiment performed. *P<0.05, **P<0.01 and ***P<0.001 indicate that expression difference between the two cellular 
conditions was statistically significant. Results of one representative experiment of two independent experiments are shown.
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(Fig. 5D and F), and for SMAD2 DMR, 74.19% of CpGs anal-
ysed showed a hypomethylation trend in sorafenib-treated 
cells, and 9.68% of CpGs analysed showed a hypermeth-
ylation trend (Fig. 5E). Therefore, the assay confirmed the 
hypomethylation trend of FOXO3, SMAD2 and TSC2 DMRs 
found by MeDip-chip experiment.
To compare the results obtained in other sorafenib-sensitive 
HCC cell lines, we extended some validation analysis by 
COBRA assay and direct bisulfite sequencing to SKHep1C3 
cells BIRC3 and MAPK3 resulted hypermethylated in line with 
HA22T/VGH cells (Figs. 4D and 5A and B). TSC2 displayed 
substantially unchanged DNA methylation level (Fig. 5C); 
finally, FOXO3 and SMAD2 showed an opposite DNA meth-
ylation trend respect to HA22T/VGH cells (Fig. 5D-E).
RT-qPCR expression analysis of the genes BIRC3, FOXO3, 
MAPK3, SMAD2 and TSC2 in sorafenib-treated and 
untreated HCC cells. To evaluate the relationship between 
Figure 4. Continued. Validation of MeDip-chip results by COBRA assay in sorafenib treated and untreated HCC cells. (C) The DMR associated to TSC2 
gene was 3,403 bp long and the primers were designed to amplify a 577 bp fragment from nucleotides 1,107 to 1,684 relative to the DMR start. The digested 
bands (382 and 195 bp) indicate the presence of methylation (red arrows). The band at the top (577 bp) corresponds to undigested DNA (black arrow). The 
histograms indicate the level of methylation in cytosine 196 in sorafenib-treated cells and untreated cells by COBRA analysis. The results indicated a slight 
hypomethylation of cytosine 196 in sorafenib treated cells. All the assays were performed using 3.0% gel in 1X TBE. The COBRA analysis was also conducted 
in sorafenib treated and untreated SKHep1C3 cells. In SKHep1C3 (D) cells the DMR associated to MAPK3 gene was found hypermethylated in sorafenib 
treated cells compared to untreated cells. In particular, the results indicated a hypermethylation of cytosine 53 in sorafenib treated cells. All the assays were 
performed using 3.0% gel in 1X TBE. Error bars of the histograms are referred to standard deviation of the means of two experiment performed. *P<0.05, 
**P<0.01 and ***P<0.001 indicate that expression difference between the two cellular conditions was statistically significant. N.S means that the results was not 
statistically significant. Results of one representative experiment of two independent experiments are shown.
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DNA methylation changes and gene expression in sorafenib-
treated and untreated cells, we evaluated the mRNA expression 
of the genes whose DNA methylation status was previously 
validated by COBRA and direct bisulfite sequencing (BIRC3, 
FOXO3, MAPK3, SMAD2 and TSC2) by RT-qPCR. The 
results showed that the 5 genes studied were differentially 
expressed in cells treated with sorafenib compared to untreated 
cells (Fig. 6A). In particular, BIRC3, FOXO3 and SMAD2 were 
upregulated while MAPK3 and TSC2 were downregulated. 
FOXO3, MAPK3 and SMAD2 showed an inverse relationship 
between gene expression and DNA methylation level with 
FOXO3 and SMAD2 being hypomethylated and upregulated 
Figure 5. Validation of MeDip-chip results by direct bisulfite sequencing in sorafenib-treated and -untreated HCC cells. Forward sequencing chromatogram 
peaks for thymine (unmethylated) and cytosine (methylated) or reverse sequencing chromatogram peaks for adenine (unmethylated) and guanine (methylated) 
were compared in bisulfite treated DNA to determine the average level of methylation for each CpG within a given sample. The white and black circles indicate 
that the mean level of CpG methylation in sorafenib-treated cells was lower (hypomethylation) or higher (hypermethylation) respect to untreated cells. Grey 
circles indicate that the mean level of CpG methylation was the same in the two cellular conditions (difference <0.1% was not considered relevant). Red circles 
indicate undetected CpGs. *P<0.05 and **P<0.01 indicate that methylation difference between the two cellular conditions was statistically significant. (A) For 
BIRC3 in HA22T/VGH, 4 out 7 CpGs showed a hypermethylation trend in sorafenib treated cells, while 1 of 7 CpGs showed a hypomethylation trend. For 
BIRC3 in SKHep1C3, 4 out 7 CpGs showed a hypermethylation trend in sorafenib-treated cells, while 2 of 7 CpGs showed a hypomethylation trend. The primer 
set was designed to amplify a 758 bp fragment from nucleotides 1,032 to 1,790 relative to the DMR start. (B) For MAPK3 in HA22T/VGH, 10 out 11 CpGs 
showed a hypermethylation trend in sorafenib-treated cells, while 0 out 11 CpGs showed a hypomethylation trend. For MAPK3 in SKHep1C3, 7 out 10 CpGs 
showed a hypermethylation trend in sorafenib-treated cells, while 3 out 10 CpGs showed a hypomethylation trend. The primer set was designed to amplify a 
430 bp fragment from nucleotides 1,660 to 2,090 relative to the DMR start. (C) For TSC2 in HA22T/VGH, 21 out 25 CpGs showed a hypomethylation trend 
in sorafenib-treated cells, while 2 out 25 CpGs showed a hypermethylation trend. For TSC2 in SKHep1C3, 11 out 25 CpGs showed a hypomethylation trend in 
sorafenib-treated cells, while 14 out 25 CpGs showed a hypermethylation trend. The primer set was designed to amplify a 577 bp fragment from nucleotides 
1,107 to 1,684 relative to the DMR start. (D) For FOXO3 in HA22T/VGH, 28 out 43 CpGs showed a hypomethylation trend in sorafenib-treated cells, while 
11 of 43 CpGs showed a hypermethylation trend. For FOXO3 in SKHep1C3, 12 out 43 CpGs showed a hypomethylation trend in sorafenib-treated cells, while 
24 of 43 CpGs showed a hypermethylation trend. The primer set was designed to amplify a 430 bp fragment from nucleotides 1,780 to 2,242 relative to the 
DMR start.
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and MAPK3 was hypermethylated and downregulated in 
sorafenib-treated compared to untreated cells. The DMR 
of FOXO3 (MAT score = -10.33; RQ=3.24) and SMAD2 
(MAT score = -10.86; RQ=1.95) were located in the promoter 
region of their associated genes, and their hypomethylation in 
sorafenib-treated cells were associated with an upregulation 
of their mRNA. These results were expected because of the 
well-known effect on gene expression of inhibition of DNA 
methylation in promoter regions. BIRC3 and TSC2 showed a 
direct relationship between DNA methylation level and gene 
expression. BIRC3 was hypermethylated and upregulated and 
TSC2 was hypomethylated and downregulated. We performed 
the RT-qPCR analysis in SKHep1C3 cells to compare the 
results obtained in HA22T/VGH cell line. SKHep1C3 cells 
displayed the same expression trend found in HA22T/VGH 
cells for BIRC3, FOXO3, SMAD2 and TSC2 and the inverse 
expression trend for MAPK3 (Fig. 6B).
Discussion
Sorafenib is the first multi-kinase inhibitor designed to 
inhibit the activity of RAF kinase, and is currently the only 
Figure 5. Continued. Validation of MeDip-chip results by direct bisulfite sequencing in sorafenib treated and untreated HCC cells. (E) For SMAD2 in HA22T/
VGH, 23 out 31 CpGs showed a hypomethylation trend in sorafenib-treated cells, while 3 out 31 CpGs showed a hypermethylation trend. For SMAD2 in 
SKHep1C3, 6 out 31 CpGs showed a hypomethylation trend in sorafenib-treated cells, while 16 out 31 CpGs showed a hypermethylation trend. The primer 
set was designed to amplify a 404 bp fragment from nucleotides 2,118 to 2,581 relative to the DMR start. (F) Examples of chromatogram peaks for thymine 
(unmethylated) and cytosine (methylated; forward sequencing) and for adenine (unmethylated) and guanine (methylated; reverse sequencing) relative to CpGs 
whose mean differences in DNA methylation were statistically significant between the two cellular conditions.
Table VI. Genes validated by quantitative COBRA assay and direct bisulfite sequencing.
     No. of CpG
  DMR  DMR CpG in observed/CpG  MAT DMR
Gene Chr start DMR end length DMR expected P-value score position
BIRC3 chr11 101693878 101695822 1944   25 0.27 1.29E-04 +12.10 Gene body: 
         Intronic
FOXO3  chr 6 108987593 108990713 3120 312 0.87 2.77E-04 -10.33 Promoter region
MAPK3 chr16 30037080 30039335 2255   29 0.21 1.11E-04 +12.42 Gene body: 
         Intronic and exonic
SMAD2 chr18 43709687 43712269 2582 228 0.94 1.66E-04 -10.86 Promoter region
TSC2 chr16 2043747 2047150 3403 121 0.40 3.69E-05 -13.04 Gene body: 
         Intronic and exonic
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treatment option for advanced and/or unresectable hepatocel-
lular carcinoma. Although SHARP (3) and other clinical trials 
confirmed the effectiveness of sorafenib compared to placebo, 
the median survival was nearly 3 months longer for patients 
treated with sorafenib than for those given placebo. Moreover, 
sorafenib had severe side effects and patients developed resis-
tance quickly (7). It is well known that epigenetic alterations 
in addition to genetic mutations play an additive role in the 
development and progression of cancer.
To our knowledge, there are no studies about sorafenib 
effects on global DNA methylation changes in cancer cells. In 
this novel study, conducted on HCC derived cells (the undif-
ferentiated HA22T/VGH cells) the data obtained showed 
that sorafenib mediated DNA methylation variations in 
1280 regions corresponding to 1230 unique genes. We consider 
this the main novelty of our work. Data obtained with functional 
enrichment analysis suggested for the first time that sorafenib 
in HA22T/VGH cells affected the methylation level of different 
genes known to be associated with tumorigenesis and/or cancer 
progression (i.e. in apoptosis, invasion and angiogenesis and 
important signaling pathways deregulated in HCC).
Apoptosis. Several studies showed that sorafenib induced 
apoptosis in different types of cancer cell lines, including HCC 
cells (6). Our results showed that different genes involved in 
apoptosis were differentially methylated after the treatment 
with sorafenib. We found hypomethylation of FOXO3, SMAD2 
and hypermethylation of CDKN1A (p21) (Fig. 7A). FOXO3 is a 
transcription factor with pro-apoptotic function. Lu et al found 
that FOXO3 was downregulated in HCC tissue (17). Moreover, 
Wehler et al found that sorafenib-sensitive colorectal cancer 
cells were defined by medium-strong FOXO3 protein expres-
sion (18). We examined FOXO3 gene expression in 2 sorafenib 
HCC treated cell lines. We have found hypomethylation of 
FOXO3 and a correspondent upregulation of its mRNA in 
HA22T/VGH cells likely leading to increased protein expres-
sion levels. In SKHep1C3, we found hypermethylation of 
FOXO3 by bisulfite sequencing and upregulation of mRNA. 
In this regard, we sequenced a small region (462 bp) of the 
DMR (differential methylated region) that was 3120 bp long. 
For this reason, we do not exclude to find hypomethylation 
within the DMR in other portions; however, other molecular 
mechanisms may be responsible of FOXO3 mRNA increasing 
in SKHep1C3.
We observed the hypomethylation of FOXO3 and the 
upregulation of FOXO3 mRNA in 2 sorafenib-treated cell lines 
and these events may determine FOXO3 protein up regulation. 
The role of SMAD2 as TSG or OG is still controversial and 
depends on the cellular context (19). When Smad proteins 
are activated by TGF-β, they form a complex with FOXO 
proteins and turn on the growth inhibitory genes p15INK4B 
and p21Cip1 (19). We found that SMAD2 was hypomethylated 
in sorafenib-treated cells and its mRNA was upregulated in 
both cell lines analyzed. Conversely, we found p21 (CDKN1A) 
hypermethylated. This result is intriguing because p21 
is a pleiotropic protein and can also have anti-apoptotic 
activity (20). Weiss et al found that sorafenib decreased p21 
expression both in renal cell carcinoma and in HCC cell lines, 
suggesting that the decrease of p21 protein is at least in part 
responsible for the high cytotoxicity of sorafenib (20).
Invasion. Sorafenib is known to inhibit invasion in HCC 
cells. Ha et al reported that sorafenib inhibits migration and 
invasion of HCC cells through suppression of different MMP 
expression (21). Moreover, Chiang et al demonstrated that 
the invasion promoted by TPA (12-O-tetradecanoylphorbol-
13-acetate) that induced MMP-9 and VEGF expression was 
inhibited by sorafenib via the suppression of ERK/NF-κB 
pathway in HCC cells (22). We found that sorafenib promoted 
the hypermethylation of crucial genes implicated in invasion 
process such as MMP3, MMP7, RAC1, RHOC and LGALS3 
(Fig. 7B). MMP3 and MMP7 are well known proteases impli-
cated in the degradation of ECM and invasion process. RAC1 
is known to be involved in various cellular functions such as 
cell growth, division, morphology, polarity and migration, 
and its overexpression was correlated with poor prognosis 
in HCC (23). RHOC was found overexpressed in HCC and it 
Figure 6. Evaluation of mRNA expression by RT-qPCR in sorafenib treated 
and untreated HCC cells. The mRNA expression of the genes BIRC3, 
FOXO3, MAPK3, SMAD2 and TSC2 was evaluated in HA22T/VGH (A) and 
SKHep1C3 (B) sorafenib-treated and untreated cells by RT-qPCR, to estab-
lish the relationship between DNA methylation changes and gene expression. 
Relative expression was calculated using ∆∆Ct method and an untreated cell 
sample as a reference. The housekeeping gene YWHAZ was used. Error bars 
of the RQ panels refer to standard deviation of the RQ means of the two 
experiment performed. *P<0.05, **P<0.01 and ***P<0.001 indicate that the 
expression difference between the two cellular conditions was statistically 
significant.
INTERNATIONAL JOURNAL OF ONCOLOGY  51:  128-144,  2017142
had an important role in invasion and metastasis (24). Finally, 
downregulation of LGALS3 was demonstrated to cause a 
decrease of uPAR levels and inhibits the proliferation, migra-
tion and invasion of HCC (25).
Angiogenesis. Anti-angiogenic activity of sorafenib is well 
documented in HCC (6). Our results showed that the pro-
angiogenic factor EPAS1 was hypermethylated in our study. 
EPAS1 is an oncogene that works in response to hypoxic condi-
tions and is overexpressed in HCC (26). Cervello et al found 
that EPAS1 mRNA resulted downregulated after treating 
HCC cells with sorafenib (27).
JAK-STAT pathway. In mammals, the JAK/STAT pathway 
is the principal signaling mechanism for a wide array of 
cytokines and growth factors. JAK activation stimulates cell 
proliferation, differentiation, cell migration and apoptosis (28). 
Yang et al found that sorafenib caused dephosphorylation of 
STAT3 and downregulation of cyclin D3 (CCND3) in glio-
blastomas (29). The downregulation of cyclin D3 mRNA after 
sorafenib treatment was reported by Cervello et al in HCC 
cells (27). We found the hypermethylation of the following 
component of JAK-STAT signaling after sorafenib treatment: 
JAK1, STAT3, STAT5A, STAT5B and CCND3 (Fig. 7D). 
Noteworthy, CCND3, a key component for G1/S phase transi-
tion, is induced by the transcription factor STAT3 and STAT5 
here both were found hypermethylated.
MAPK pathway: RAF/MEK/ERK cascade. Sorafenib was 
initially designed to inhibit the kinase activity of RAF 
and consequently the RAF/MEK/ERK cascade involved 
in different processes of survival and cellular growth. 
Liu et al demonstrated that sorafenib blocked the RAF/MEK/
ERK pathway by inhibiting the phosphorylation of MEK 
and ERK and it downregulated cyclin D1 levels in two HCC 
cell lines (6). We observed MAPK3 (ERK1) and MAP2K2 
(MEK2) hypermethylated in sorafenib treated HA22T/VGH 
cells. We also found FOS, one of the effectors of RAF/MEK/
ERK cascade, hypermethylated (Fig. 7E). Walter et al found 
the downregulation of FOS in human osteosarcoma cells after 
sorafenib treatment (30). 
PI3K/AKT pathway. PI3K/AKT signaling is an important 
survival/proliferative pathway involving various growth 
factors, cytokines, and activation of receptors and it is one 
of the most commonly activated signaling pathway in human 
Figure 7. Genes associated to tumorigenesis and/or cancer progression found differentially methylated in HA22T/VGH sorafenib treated cells. The genes are 
grouped based on their role: apoptosis (A), invasion (B) and angiogenesis (C) as well as genes belonging to several signaling pathways such as JAK-STAT (D), 
RAF/MEK/ERK (E), PI3K/AKT (F), JNK (G) and NF-κB (H). Generally, we found a trend where oncogenes were hypermethylated and TSG were hypometh-
ylated after sorafenib treatment. In light blue and red are reported genes found hypomethylated or hypermethylated, respectively. Genes known to be TSG are 
underlined while genes known to be oncogenes are not underlined. Green and red lines indicate the activation or inhibition of a gene product or a signaling 
pathway, respectively.
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cancer. However, the role of this pathway in the mechanisms of 
action of sorafenib is not fully elucidated. Gedaly et al showed 
that sorafenib enhance the level of p-AKT in HCC HuH7 
cells (31). However, Zhang et al found opposite results using 
Human SMMC-7721 hepatic carcinoma cells. They found that 
sorafenib inhibited hepatic tumor growth by reducing PI3K/
AKT signaling pathway (32). Furthermore, Cervello et al found 
no variation of p-AKT in HCC HepG2 cell line treated with 
sorafenib (27). In this context, we found DNA methylation 
changes in different component of PI3K/AKT pathway, but 
with no clear tendency to turn on or turn off this pathway in 
HA22T/VGH treated with sorafenib. We found PIK3CA and 
PIK3C2B, subunits of PI3K, hypermethylated (Fig. 7F). We 
found TSC2, inhibitor of mTOR, hypomethylated (Fig. 7F), 
although the mRNA validation showed a downregulation of 
the TSC2 mRNA in the 2 cell lines analyzed.
Concerning the correlation between DNA methylation 
and mRNA expression, our results indicated that among 
the 5 selected genes BIRC3 and TSC2 displayed a direct 
trend between DNA methylation and mRNA expression and 
FOXO3, MAPK3 and SMAD2 showed an inverse trend in 
HA22T/VGH cells.
In our study the DMR of BIRC3, MAPK3 and TSC2 were 
located in intragenic regions and the analysis of gene expres-
sion of associated genes returned both positive and negative 
relationship between transcription and intragenic DNA 
methylation. Some authors have already described that DNA 
methylation in intragenic regions can lead to both positive 
and negative relationship between transcription and intra-
genic DNA methylation (33). BIRC3 (MAT score = +12.10; 
RQ=9.22) and TSC2 (MAT score = -13.04; RQ=0.27) showed 
the same direct trend, while MAPK3 (MAT score = +12.42; 
RQ=0.41) showed an inverse trend between gene expression 
and DNA methylation. Moreover, the DMR of BIRC3 and 
MAPK3 contained fewer CpGs and were located near CpG 
islands. In literature, the regions that flank CpG islands with 
less CG density have been recently described as ‘CpG island 
shores’. Different studies have described the role of CpG island 
shore methylation in cancer and how it can affect gene expres-
sion. For example, Irizarry et al reported that most of the 
methylation differences between normal and cancer samples 
occur in CpG island shores (34). To our knowledge this is the 
first time that the association between CpG island shore meth-
ylation and changes of gene expression in HCC cells treated 
with sorafenib has been reported although further studies are 
needed to confirm these findings.
Since the methylome of SKHep1C3 was not analyzed, we 
do not assume that sorafenib determines the same global DNA 
methylation changes observed in HA22T/VGH cells even if 
this cell line is sorafenib-sensitive. It would be of interest in the 
future to identify the DMRs in different HCC cell lines in order 
to know the common DMRs and those depending on their own 
malignant characteristics and on their differentiation state. In 
this regard, the DNA methylation variations of the 5 selected 
genes in SKHep1C3 cells displayed a partial overlap compared 
to those obtained in HA22T/VGH cells, but importantly their 
expression levels were affected. In SKHep1C3 the trend of 
the gene expression dysregulation was concordant in 4 out 5 
genes in respect to HA22T/VGH cells although not statistically 
significant for BIRC3 and SMAD2. Further, in SKHep1C3, 
we found hypermethylation of FOXO3 by bisulfite sequencing 
and upregulation of mRNA. In this regard, we outline that we 
sequenced a small region (462 bp) of the DMR (differential 
methylated region) that was 3120 bp long. For this reason, we do 
not exclude to find hypomethylation within the DMR in other 
portions; however, some other mechanisms of gene expres-
sion control, other than DNA methylation, such as histone 
modifications, chromatin remodelling and post-transcriptional 
regulation (i.e. ncRNAs) should not to be excluded in deter-
mining mRNA dysregulation following sorafenib treatments.
In summary, this is the first study that analyzed the global 
DNA methylation changes induced by sorafenib in cancer cells 
in particular in the HCC sorafenib sensitive HA22T/VGH 
cells. Our data show that sorafenib affected the DNA meth-
ylation status of numerous genes involved in tumorigenesis 
and cancer progression, with a general trend of oncogenes to 
be hypermethylated and tumor suppressor genes to be hypo-
methylated. These genes are involved in processes such as 
apoptosis, invasion and angiogenesis, and different signaling 
pathways deregulated in HCC.
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